Boston Scientific faces more questions over Watchman implant's effectiveness, risks

December 9, 2013 by Arezu Sarvestani

Healthcare regulators will take a closer look at missed efficacy endpoints and surgical risks associated with Boston Scientific's Watchman anti-stroke heart implant, which is slated this week to undergo FDA advisory panel review.

Boston Scientific faces more FDA questions over Watchman heart implant's risks

Boston Scientific (NYSE:BSX) may have to confront some tough questions when it faces a panel of FDA experts reviewing its Watchman stroke-preventing heart implant.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp